Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.30 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930696 | 0.86 | AOC2 (0.32) | AOC2MAOAAKT1PIK3CAMTOR | |
| SCHEMBL15970327 | 0.81 | — | — | |
| SCHEMBL23160212 | 0.78 | INPP5A (0.44) | AOC2MAOAAKT1PIK3CAMTOR | |
| SCHEMBL4771641 | 0.78 | AOC2 (0.38) | AOC2MAOAAKT1PIK3CAMTOR | |
| SCHEMBL23012533 | 0.78 | INPP5A (0.44) | AOC2MAOAAKT1PIK3CAMTOR | |
| SCHEMBL18665543 | 0.78 | AOC2 (0.35) | AOC2MAOAAKT1PIK3CAMTOR | |
| SCHEMBL1647665 | 0.78 | INPP5A (0.44) | AOC2MAOAAKT1PIK3CAMTOR | |
| SCHEMBL6962281 | 0.77 | AOC2 (0.37) | AOC2MAOAAKT1PIK3CAMTOR | |
| SCHEMBL6962289 | 0.77 | INPP5A (0.42) | AOC2MAOAAKT1PIK3CAMTOR | |
| SCHEMBL13021 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637450-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | GLOBAL CANCER TECHNOLOGY INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-3774783-B1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | NEUROPORE THERAPIES INC (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20240327396-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | NEUROPORE THERAPIES, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-12049462-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | NEUROPORE THERAPIES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-117858879-A | CDK2/4/6 inhibitor and preparation method and application thereof | 南京再明医药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-112189012-B | Trisubstituted aryl and heteroaryl derivatives as modulators of PI3 kinase and autophagy pathways | 神经孔疗法股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230265086-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | NEUROPORE THERAPIES, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265086-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | NEUROPORE THERAPIES, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-11492348-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | NEUROPORE THERAPIES, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20210163462-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | NEUROPORE THERAPIES, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| WO-2019199864-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | NEUROPORE THERAPIES, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| EP-3349579-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd. (CN) | 2018-07-25 | — | — | EP | disclosed |
| US-20170081338-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-03-23 | — | — | US | disclosed |
| WO-2017048675-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-03-23 | — | — | WO | disclosed |
| WO-2016132134-A1 | THIAZOLE DERIVATIVES FOR THE TREATMENT OF ANIMAL TRYPANOSOMIASIS | UNIVERSITY OF DUNDEE (GB) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016132134-A1 | THIAZOLE DERIVATIVES FOR THE TREATMENT OF ANIMAL TRYPANOSOMIASIS | UNIVERSITY OF DUNDEE (GB) | 2016-08-25 | — | — | WO | disclosed |
| EP-1060178-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6610707-B1 | Moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases and nerve damage. | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1060178-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999045006-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492348-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | ATG7, ULK1, BECN1 | AOC2 3178/4885MAOA 2046/4885AKT1 34/4885 |
| US-20210163462-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | ATG7, ULK1, BECN1 | AOC2 3178/4885MAOA 2046/4885AKT1 34/4885 |
| US-12637450-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | PIK3R4, PIK3R1, ATG7 | AOC2 1447/4885MAOA 3500/4885AKT1 32/4885 |
| US-20240327396-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | ATG7, ULK1, BECN1 | AOC2 3178/4885MAOA 2046/4885AKT1 34/4885 |
| US-12049462-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | ATG7, ULK1, BECN1 | AOC2 3204/4885MAOA 2002/4885AKT1 34/4885 |
| US-20170081338-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | PRKACA, PRKDC, PRKACB | AOC2 4433/4885MAOA 2687/4885AKT1 122/4885 |
| US-20230265086-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | ATG7, ULK1, BECN1 | AOC2 3178/4885MAOA 2046/4885AKT1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.